<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657785</url>
  </required_header>
  <id_info>
    <org_study_id>NavyGHB-001</org_study_id>
    <secondary_id>001</secondary_id>
    <nct_id>NCT02657785</nct_id>
  </id_info>
  <brief_title>Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy</brief_title>
  <official_title>Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navy General Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navy General Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high
      effective in primary central nervous system lymphoma (PCNSL) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will evaluate response rate, progression free survival (PFS), overall
      survival (OS), and toxicity in primary central nervous system lymphoma (PCNSL) after systemic
      and intrathecal immunochemotherapy with deferred radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3year Overall survival</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-IDARAM plus intrathecal chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-IDARAM plus intrathecal chemotherapy</intervention_name>
    <description>R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.</description>
    <arm_group_label>R-IDARAM plus intrathecal chemotherapy</arm_group_label>
    <other_name>R-IDARAM plus intrathecal immuochemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).

        Exclusion criteria:

          -  Involved sites other than the brain, meninges, CSF, or the eyes.

          -  Age less than 18 years or greater than 75 years.

          -  Inadequate bone marrow capacity (defined as neutrophils&lt;1.5 ×10^9/L, platelets &lt;100
             ×10^9/L, and hemoglobin level&lt; 8 g/dL).

          -  Known cause of immunosuppression (ie, HIV type I infection).

          -  Any previous malignancy.

          -  Creatinine clearance below 60 mL/min.

          -  Heart insufficiency (NYHA IIIB or IV).

          -  Uncontrolled infection.

          -  Noncompensated active pulmonary or liver disease.

          -  Previously treated for PCNSL, except by corticosteroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liren Qian, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Navy General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Navy General Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Liren Qian</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

